Big Enough for an Aromatase Inhibitor? How Adiposity Affects Male Fertility

Sahar M. Stephens; Alex J. Polotsky

doi:10.1055/s-0033-1345272

Seminars in Reproductive Medicine, Inhaltsverzeichnis

Semin Reprod Med 2013; 31(04): 251-257
DOI: 10.1055/s-0033-1345272

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Big Enough for an Aromatase Inhibitor? How Adiposity Affects Male Fertility

Sahar M. Stephens

¹Department of Obstetrics and Gynecology, University of Colorado, Denver, Colorado

,

Alex J. Polotsky

¹Department of Obstetrics and Gynecology, University of Colorado, Denver, Colorado

› Institutsangaben

Abstract

Obesity is a pandemic and is associated with multiple medical problems including subfertility. Male obesity has been associated with altered semen parameters and reproductive hormonal levels, including a reduced testosterone:estradiol (T:E₂) ratio. Treatment methods employed for obesity-related male subfertility include gonadotropin administration, weight loss, and aromatase inhibitors. Letrozole is a highly effective nonsteroidal aromatase inhibitor that has been used to treat male subfertility in several case series with promising results. Adequately designed randomized controlled studies are needed to produce evidence-based data on the role of aromatase inhibitors in male subfertility management and evaluate the side-effect profile.

Keywords

male obesity - infertility - aromatase inhibitor - letrozole

Volltext

Referenzen

References
1 Hammoud AO, Gibson M, Peterson CM, Meikle AW, Carrell DT. Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril 2008; 90 (4) 897-904
2 US Department of Health and Human Services. Final review, healthy people 2010: Nutrition and overweight. Available at: http://www.cdc.gov/nchs/data/hpdata2010 . Accessed on April 29, 2013
3 Organization TWH. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii , 1–253
4 Ode JJ, Pivarnik JM, Reeves MJ, Knous JL. Body mass index as a predictor of percent fat in college athletes and nonathletes. Med Sci Sports Exerc 2007; 39 (3) 403-409
5 Okorodudu DO, Jumean MF, Montori VM , et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010; 34 (5) 791-799
6 Organization TWH. Obesity and Overweight. WHO Media Centre; 2011
7 Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update 2003; 9 (4) 359-372
8 Jensen TK, Andersson AM, Jørgensen N , et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril 2004; 82 (4) 863-870
9 Nguyen RH, Wilcox AJ, Skjaerven R, Baird DD. Men's body mass index and infertility. Hum Reprod 2007; 22 (9) 2488-2493
10 Ramlau-Hansen CH, Thulstrup AM, Nohr EA, Bonde JP, Sørensen TI, Olsen J. Subfecundity in overweight and obese couples. Hum Reprod 2007; 22 (6) 1634-1637
11 Sallmén M, Sandler DP, Hoppin JA, Blair A, Baird DD. Reduced fertility among overweight and obese men. Epidemiology 2006; 17 (5) 520-523
12 Speakman JR, Djafarian K, Stewart J, Jackson DM. Assortative mating for obesity. Am J Clin Nutr 2007; 86 (2) 316-323
13 Bakos HW, Henshaw RC, Mitchell M, Lane M. Paternal body mass index is associated with decreased blastocyst development and reduced live birth rates following assisted reproductive technology. Fertil Steril 2011; 95 (5) 1700-1704
14 Keltz J, Zapantis A, Jindal SK, Lieman HJ, Santoro N, Polotsky AJ. Overweight men: clinical pregnancy after ART is decreased in IVF but not in ICSI cycles. J Assist Reprod Genet 2010; 27 (9–10) 539-544
15 Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for decreasing quality of semen during past 50 years. BMJ 1992; 305 (6854) 609-613
16 Swan SH, Elkin EP, Fenster L. The question of declining sperm density revisited: an analysis of 101 studies published 1934-1996. Environ Health Perspect 2000; 108 (10) 961-966
17 MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update 2010; 16 (3) 293-311
18 Sermondade N, Faure C, Fezeu L, Lévy R, Czernichow S. Obesity-Fertility Collaborative Group. Obesity and increased risk for oligozoospermia and azoospermia. Arch Intern Med 2012; 172 (5) 440-442
19 Teerds KJ, de Rooij DG, Keijer J. Functional relationship between obesity and male reproduction: from humans to animal models. Hum Reprod Update 2011; 17 (5) 667-683
20 Amatruda JM, Hochstein M, Hsu TH, Lockwood DH. Hypothalamic and pituitary dysfunction in obese males. Int J Obes 1982; 6 (2) 183-189
21 Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76 (5) 1140-1146
22 Jain A, Polotsky AJ, Rochester D , et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab 2007; 92 (7) 2468-2473
23 Dhillo WS, Chaudhri OB, Patterson M , et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005; 90 (12) 6609-6615
24 George JT, Millar RP, Anderson RA. Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology 2010; 91 (4) 302-307
25 Hammoud A, Carrell D, Gibson M, Peterson C, Meikle A. Updates on the relation of weight excess and reproductive function in men: sleep apnea as a new area of interest. Asian J Androl 2012; 14: 77-81
26 Kamischke A, Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod 1999; 14 (Suppl. 01) 1-23
27 Attia AM, Al-Inany HG, Farquhar C, Proctor M. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2007; (4) CD005071
28 Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 1981; 53 (4) 828-832
29 Strain GW, Zumoff B, Miller LK , et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 1988; 66 (5) 1019-1023
30 Hammoud A, Gibson M, Hunt SC , et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab 2009; 94 (4) 1329-1332
31 di Frega AS, Dale B, Di Matteo L, Wilding M. Secondary male factor infertility after Roux-en-Y gastric bypass for morbid obesity: case report. Hum Reprod 2005; 20 (4) 997-998
32 Sermondade N, Massin N, Boitrelle F , et al. Sperm parameters and male fertility after bariatric surgery: three case series. Reprod Biomed Online 2011; 2012; 24 (2) 206-210
33 Palmer NO, Bakos HW, Owens JA, Setchell BP, Lane M. Diet and exercise in an obese mouse fed a high-fat diet improve metabolic health and reverse perturbed sperm function. Am J Physiol Endocrinol Metab 2012; 302 (7) E768-E780
34 Elkhiat Y, Fahmy I. Aromatase inhibitors in the treatment of male infertility. Human Andrology 2011; 1: 35-38
35 Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167 (2, Pt 1) 624-629
36 de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol 2011; 9: 93
37 Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003; 52 (9) 1126-1128
38 Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab 2008; 4 (7) 415-419
39 Patry G, Jarvi K, Grober ED, Lo KC. Use of the aromatase inhibitor letrozole to treat male infertility. Fertil Steril 2009; 92 (2) e1-e2
40 Cavallini G, Beretta G, Biagiotti G. Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH. Asian J Androl 2011; 13 (6) 895-897
41 de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 2005; 7 (3) 211-215
42 Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008; 158 (5) 741-747
43 Richardson D, Goldmeier D, Frize G , et al. Letrozole versus testosterone. a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med 2007; 4 (2) 502-508
44 Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011; 95 (2) 809-811
45 Gonzales GF, Tapia V, Gasco M, Gonzales-Castañeda C. Aromatase activity after a short-course of letrozole administration in adult men at sea level and at high altitude (with or without excessive erythrocytosis). Horm Metab Res 2012; 44 (2) 140-145
46 Lapauw B, T'Sjoen G, Mahmoud A, Kaufman JM, Ruige JB. Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men. Eur J Endocrinol 2009; 160 (3) 397-402